Bioceres Crop Solutions Corp logo

Bioceres Crop Solutions Corp(BIOX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.2
10/26/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BIOX

10/26/2026: BIOX (1-star) is currently NOT-A-BUY. Pass it for now.

Bioceres Crop Solutions Corp is a specialized agricultural biotechnology company known for developing climate-resilient seed traits, most notably its HB4 drought-tolerant technology. The company has a strong foundation built on proprietary R&D and an established commercial platform for biological crop inputs, which helps support its growth. Its primary investment story centers on the global expansion and licensing of its HB4 traits to increase productivity in farming. However, investors must consider risks including geographic concentration, significant regulatory hurdles for GMO products, and competition from large multinational agricultural firms. The stock may suit growth-oriented investors, while those seeking immediate dividend income or low volatility may find less fit here.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers exposure to high-potential, innovative biotechnology traits in the agricultural sector.
Momentum investorMixed fitMomentum is highly conditional on news regarding regulatory approvals and technology adoption rates.
Value investorWeak fitThe company is currently in an aggressive growth and investment phase rather than a value-capture phase.
Dividend investorWeak fitThe company does not provide a regular dividend, as it focuses capital on R&D.
Low-risk investorWeak fitHigh volatility associated with agricultural biotechnology and geographic concentration makes it unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is susceptible to fluctuations based on harvest results and commodity price changes.
Valuation riskMediumMarket pricing heavily discounts future success of new traits like HB4.
Competition risk (Global Ag-Biotech giants)HighLarge incumbents possess greater resources to defend market share.
Business qualityMediumWhile the technology is innovative, the business is still scaling and sensitive to regional economic conditions.
Dividend incomeLow / noneThere is no expectation of dividend income for shareholders.
Execution riskMedium / highScaling technology adoption across global regulatory landscapes is complex.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -38.98%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 10/26/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BIOX receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
BIOX has moderate overall fundamentals (3 stars), with moderate financial health, weak growth momentum, and solid ownership. In FY2026 versus FY2025, growth and ownership metrics are mixed: negative earnings growth (-315.6%), soft cash generation (FCF margin 0.0%), negative revenue growth (-28.7%).

Financial Health Rating

★★★★★
BIOX's financial health is supported by moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 34.6% of revenue). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
BIOX's growth profile is soft, with the least-weak measure being revenue growth at -28.7% FY2026 versus FY2025. By comparison, while earnings growth (-315.6%, negative) and free-cash-flow growth (-100.0%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 23.1% and approximately 70.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 16.95% supports management-shareholder alignment.

Top 5 Institutional Investors

Solel Partners LP 7.18%
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 2.20%
Long Focus Capital Management, LLC 1.30%
Ardsley Advisory Partners 0.74%
UBS Group AG 0.64%

Unit Economics (Per $1K Revenue)

★★★★★
BIOX generates approximately $347 of gross profit, $0 of operating income, and $0 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -6.67% (Tax Credit)

Quantitative Style Profile

★★★★★
BIOX has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 14.97M USD
Price to earnings Ratio -
1Y Target Price 2
Price to earnings Ratio -
1Y Target Price 2
Volume (30-day avg) 256.0K shares
Beta 0.47
52 Weeks Range 0.19 - 2.10
Updated Date 10/26/2026
52 Weeks Range 0.19 - 2.10
Updated Date 10/26/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.74

How Company Makes Money

Business areaWhat it includesRetail investor read
Crop ProductivityHB4 seed traits and integrated seed solutions.Revenue comes from licensing and selling seeds engineered for better performance.
Crop ProtectionBiological fertilizers and chemical crop protection products.Recurring revenue from the recurring sale of farming inputs.
GeographyPrimary operations in South America with expansion efforts in North America.The company is sensitive to the success of the farming sector in the Americas.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Advertisement

Valuation

Trailing PE -
Forward PE 14.99
Enterprise Value 252.22M
Price to Sales(TTM) 0.06
Enterprise Value 252.22M
Price to Sales(TTM) 0.06
Enterprise Value to Revenue 0.86
Enterprise Value to EBITDA 17.98
Shares Outstanding 63.82M
Shares Floating 45.01M
Shares Outstanding 63.82M
Shares Floating 45.01M
Percent Insiders 16.95
Percent Institutions 23.13

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.